The original paper focused on NOTCH, a family of membrane-associated receptors that regulate cell fate, development, tissue renewal and cancer progression. In its canonical role, NOTCH signaling begins when a neighboring cell presents a ligand that binds the NOTCH receptor. This interaction triggers a sequence of proteolytic cleavages, ultimately releasing the NOTCH intracellular domain. That fragment can enter the nucleus and cooperate with transcriptional regulators to activate genes involved in proliferation, survival and cellular identity. Aberrant NOTCH activity has been implicated in several malignancies, including leukemias, breast cancer, brain tumors and other solid cancers. The retracted study proposed that NOTCH also has a direct mitochondrial role, extending the pathway beyond its well-known function in the nucleus.

Mitochondria are often described as the energy-producing structures of cells, but they also control metabolism, redox balance, calcium handling and programmed cell death. Cancer cells frequently reconfigure mitochondrial activity to survive hostile conditions, maintain rapid growth and resist therapy. Tumor-initiating cells, sometimes referred to as cancer stem-like cells, are a particularly important population because they can self-renew, generate diverse tumor cell types and contribute to relapse. The paper claimed that NOTCH could be redirected to mitochondria in these cells, where it might influence the organelle’s behavior and help preserve a tumor-initiating state. If validated, such a mechanism would have connected developmental signaling, mitochondrial biology and cancer persistence in a striking way.

Central to the reported mechanism was the interaction between TBC1D15 and FIS1. FIS1 is an outer mitochondrial membrane protein associated with mitochondrial dynamics, including the division of mitochondria into smaller units. TBC1D15 is a protein involved in membrane trafficking and has been linked to regulation of mitochondrial morphology through interactions with FIS1 and related cellular machinery. According to the retracted claim, this molecular pairing served as a route by which NOTCH localized to mitochondria. In technical terms, the proposed interaction would have placed a signaling protein traditionally studied at the plasma membrane and in the nucleus within a mitochondrial protein network, potentially allowing NOTCH to affect mitochondrial organization or signaling from inside the organelle’s immediate environment.

The study also described a stabilization mechanism involving an E3 ubiquitin ligase and CDK8. E3 ligases are enzymes that attach ubiquitin molecules to specific proteins, marking them for altered activity, transport or destruction by the proteasome. This system is one of the cell’s principal methods for controlling protein abundance. CDK8, or cyclin-dependent kinase 8, is a transcriptional regulator that functions as part of the Mediator complex and can influence gene expression programs associated with development and cancer. The paper proposed that blocking the recruitment of an E3 ligase and CDK8 to NOTCH prevented its degradation or inactivation, thereby stabilizing the protein and supporting a cellular reprogramming process linked to tumor initiation.

That proposed chain of events was potentially significant because it suggested that NOTCH could operate through two interconnected layers of control: a mitochondrial localization step and a protein-stabilization step. In principle, such a pathway might help explain how tumor-initiating cells maintain both metabolic flexibility and self-renewal capacity. It also raised the possibility that disrupting the TBC1D15-FIS1 interaction, altering mitochondrial recruitment or restoring NOTCH turnover could weaken cancer cells that depend on this state. However, these therapeutic implications relied entirely on the accuracy and reproducibility of the reported molecular interactions. Once a paper is retracted, those proposed connections must be regarded as unresolved rather than as a confirmed map of cancer biology.

A retraction is different from a routine correction. Corrections usually address limited errors that do not overturn the central conclusions of a study. Retraction, by contrast, signals that the publication should not be relied upon as part of the established scientific record. The citation supplied for this case identifies the publication as a “Retraction Note,” but it does not, by itself, provide the detailed reason or reasons for the decision. Without an official explanation specifying whether the issue involved data integrity, methodology, interpretation, authorship or another concern, it would be inappropriate to infer what went wrong. The responsible scientific position is therefore to distinguish clearly between the hypotheses described in the original title and results that have been independently confirmed.

The withdrawal is especially relevant in a field where molecular claims can rapidly influence laboratory priorities, drug-development strategies and public expectations about cancer treatments. A mechanism that appears to connect NOTCH, mitochondria and tumor-initiating cells may attract attention because it offers a single narrative linking several major areas of cancer research. Yet complex biological systems are vulnerable to experimental artifacts. Apparent protein interactions can be affected by overexpression, antibody specificity, cell-line differences, subcellular fraction contamination or conditions that do not reflect tumors in living organisms. Demonstrating mitochondrial localization, for example, generally requires complementary approaches such as high-resolution imaging, biochemical fractionation with appropriate purity controls and independent confirmation using endogenous proteins.

The retraction does not erase the importance of studying NOTCH signaling, mitochondrial dynamics or tumor-initiating cells. It does mean that the specific TBC1D15-FIS1 localization model and the proposed blockade of E3 ligase and CDK8 recruitment cannot currently serve as dependable foundations for new conclusions. Future research will need to establish whether any form of NOTCH-mediated mitochondrial regulation exists, whether it occurs in physiologically relevant cancer models and how it relates to protein degradation and transcriptional control. For now, the most accurate message is one of scientific caution: an intriguing mechanism linking a major developmental pathway to cancer-cell metabolism has been removed from the trusted literature, leaving the underlying question open for rigorous investigation.

Subject of Research: NOTCH signaling, mitochondrial localization, TBC1D15-FIS1 interaction, protein stabilization and tumor-initiating cells in cancer

Article Title: Retraction Note: NOTCH localizes to mitochondria through the TBC1D15-FIS1 interaction and is stabilized via blockade of E3 ligase and CDK8 recruitment to reprogram tumor-initiating cells.

Article References: Choi, H.Y., Zhu, Y., Zhao, X. et al. Retraction Note: NOTCH localizes to mitochondria through the TBC1D15-FIS1 interaction and is stabilized via blockade of E3 ligase and CDK8 recruitment to reprogram tumor-initiating cells. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01834-9

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01834-9

Keywords: NOTCH signaling, mitochondria, TBC1D15, FIS1, E3 ligase, CDK8, tumor-initiating cells, cancer biology, retraction, molecular oncology

Melatonin has long been the subject of intense scientific scrutiny due to its multifaceted biological roles. Beyond its established function in circadian rhythm regulation, melatonin exhibits notable antioxidant and immunomodulatory properties that have fueled investigations into its potential anti-cancer effects. The study in question pursued this line of inquiry by focusing on TLR4, a critical component of the innate immune system that triggers inflammatory responses upon detecting molecular patterns associated with pathogens or cellular damage. By examining these pathways in an in vivo ovarian cancer model, the researchers aimed to understand whether melatonin could attenuate tumor-promoting inflammation, potentially opening new avenues for cancer therapy.

The TLR4 signaling network is intricate, engaging two primary adaptor molecules: MyD88 and TRIF. These molecules initiate distinct but complementary cascades activating transcription factors that drive pro-inflammatory gene expression. Aberrant activation of this system often contributes to a tumorigenic microenvironment, fostering cancer cell survival, proliferation, and metastasis. Targeting TLR4-mediated signaling, therefore, holds therapeutic promise, especially in malignancies like ovarian cancer, where inflammation plays a significant pathogenic role.

Originally, the study reported that melatonin administration in experimental models led to a significant suppression of TLR4-driven inflammatory signaling. This effect purportedly involved downregulation of MyD88-dependent pathways, responsible for rapid activation of NF-κB and pro-inflammatory cytokines, as well as modulation of TRIF-related signaling, which influences interferon responses and late-phase inflammatory genes. Through this dual inhibitory mechanism, melatonin was suggested to exert a protective influence, reducing tumor-associated inflammation and potentially hindering ovarian cancer progression.

The research was conducted primarily by a collaborative group of investigators affiliated with prominent Brazilian institutions, including UNESP, UENP, UFSCar, UNICAMP, and CEVAP. Their integrated expertise spanned anatomy, biology, pathology, and venom studies, providing a comprehensive approach to exploring cancer immunology. The multidisciplinary team leveraged sophisticated in vivo models to mimic ovarian tumor microenvironments, employing molecular assays to dissect the complex interplay between melatonin and TLR4 signaling components at the cellular level.

Despite the initially promising results and the excitement generated by the prospect of a novel anti-inflammatory therapeutic strategy, the article was formally retracted due to concerns related to data validity and reproducibility. Retractions, while often viewed negatively, play a crucial role in maintaining the integrity of scientific literature. They prompt the research community to exercise caution, re-examining conclusions and reinforcing the importance of rigorous methodology, especially when findings have significant clinical implications.

The implications of this retraction extend beyond the specific study; they highlight the challenges inherent in translating molecular signaling insights into therapeutic interventions. The intricate network of immune signaling pathways involved in cancer is susceptible to various biological variables, experimental conditions, and analytical interpretations. As such, unraveling the precise role of molecules like melatonin requires comprehensive validation across multiple independent models and laboratories to ensure robustness and clinical relevance.

Furthermore, the retraction shines a spotlight on the imperative for transparency in the scientific process. Detailed methodological reporting, open data sharing, and collaborative verification are instrumental in advancing knowledge and fostering trust. As the field of cancer immunotherapy evolves, balancing innovation with rigor remains paramount, ensuring that new therapies are not only promising but also safe and effective.

The initial hypothesis linking melatonin to TLR4 pathway modulation remains a compelling question that continues to inspire research. Melatonin’s ability to influence immune cell function and cytokine production positions it as a candidate for further investigation. Future studies might consider alternative experimental designs, diverse model systems, and advanced molecular techniques to clarify its role in cancer-related inflammation comprehensively.

In parallel, the broader scientific effort to map the signaling circuitry of the tumor microenvironment proceeds unabated. Understanding how innate immune receptors like TLR4 engage with endogenous and exogenous factors to drive tumorigenesis is fundamental to developing precision medicine strategies. Therapies that can fine-tune immune responses hold potential to complement existing treatments, improving outcomes for patients suffering from ovarian cancer and other malignancies.

The retraction also underscores the necessity of cautious optimism in cancer research. Breakthrough findings, especially those offering affordable and accessible interventions such as melatonin, generate hope among clinicians and patients alike. However, scientific advancement is often incremental, shaped by iterative experimentation, peer review, and ongoing validation.

Scientific journals and publishers play a pivotal role in this ecosystem by providing mechanisms for correction and dialogue. The transparent publication of retraction notices, such as the one issued by BMC Cancer, facilitates an open scientific discourse. It serves as a reminder of the community’s commitment to uphold exemplary standards even amid the pressures to produce impactful results.

In conclusion, while the retraction of the melatonin and TLR4 signaling study represents a setback, it simultaneously reinforces the dynamic, self-correcting nature of science. The quest to harness immunological pathways for cancer therapy remains an active and critical field of inquiry. Researchers worldwide continue to unravel the molecular complexities of inflammation-associated cancers, employing innovative approaches and collaborations to deliver transformative treatments. The evolving narrative of melatonin’s role in ovarian cancer is emblematic of this journey—a testament to perseverance, intellectual honesty, and the relentless pursuit of truth in science.

Subject of Research: Melatonin’s modulation of TLR4-mediated inflammatory responses in ovarian cancer models.

Article Title: Retraction Note: Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.

Article References:
Chuffa, L.G.A., Fioruci-Fontanelli, B.A., Mendes, L.O. et al. Retraction Note: Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer 25, 876 (2025). https://doi.org/10.1186/s12885-025-14297-4

Image Credits: Scienmag.com